March 1, 2021 -- Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand Hologic's molecular diagnostics business internationally.
Diagenode offers clients more than 30 polymerase chain reaction (PCR) tests, as well as a portfolio of devices, kits, reagents, and antibodies for DNA and RNA analysis.
The two firms have had a partnership since 2016 and have collaborated on Panther Fusion assays for group B Streptococcus and Bordetella. Diagenode generated more than $30 million in revenue in the last year, Hologic said.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current